TD Cowen Keeps Their Hold Rating on Milestone Pharmaceuticals (MIST)
In a report released today, Ritu Baral from TD Cowen maintained a Hold rating on Milestone Pharmaceuticals. The company’s shares opened today at $1.74.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Krystal Biotech, and Alnylam Pharma. According to TipRanks, Baral has an average return of 12.5% and a 48.49% success rate on recommended stocks.
Currently, the analyst consensus on Milestone Pharmaceuticals is a Moderate Buy with an average price target of $4.50.
The company has a one-year high of $2.75 and a one-year low of $0.63. Currently, Milestone Pharmaceuticals has an average volume of 1.39M.
Read More on MIST:
Disclaimer & DisclosureReport an Issue
- Milestone Pharmaceuticals Reports Increased Loss Amid R&D Focus
- Milestone Pharmaceuticals: Strong Buy Rating Backed by Anticipated Cardamyst Approval and Robust Financial Position
- Milestone Pharmaceuticals Advances CARDAMYST with FDA and Financial Boost
- Milestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)
- Milestone Pharmaceuticals’ Cardamyst NDA Resubmission Boosts Buy Rating Amid FDA Progress
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.